Co-Founder, Sakti3
President and CEO of the Central Indiana Corporate Partnership
Managing Director, D.E. Shaw and Co., L.P.
Founder and Managing Partner, Frazier Healthcare Ventures
VP of Research and Special Initiatives, Google
Founder and Chairman, Sycamore Networks
Managing director, the Foundry Group
VP of Research & Policy, Ewing Marion Kauffman Foundation
[Updated 11/16/18, 2:15 pm. see below] Accelerators and apprenticeships, venture deals and partnerships. Here’s a roundup of Boston technology news bits from the week. Read on:
—Nonprofit tech accelerator MassChallenge is toying with launching a for-profit entity to... Read more »
Thanksgiving is around the corner and this week delivered a bounty of deals that have a number of life science companies expressing their thanks a little early.
One deal saw a company land a whopping $800 million upfront for a rights... Read more »
If you thought Siemens’ $730 million purchase of Boston-based business app developer Mendix would have locked the digital company’s focus onto the factory floor, CEO Derek Roos wants you to know you’re wrong.
The reality, Roos claims, is that the Mendix... Read more »
A growing number of startups are trying to encourage people to share genomic and other health data for research purposes by offering them some form of compensation. Now, as competition in this young sector ramps up, one of the big questions... Read more »
The race to treat hemophilia with gene therapy, a one-time, long-lasting infusion, is entering its final stages. And with new data released this morning, Dutch and Lexington, MA, firm UniQure has finalized its plans to be among the top finishers.
UniQure... Read more »
The shaking, tremors, and loss of muscle control in some movement disorders can be traced to misfiring neurons. Cadent Therapeutics has developed a drug intended to help those neurons send signals properly. The Cambridge, MA-based company now $40 million in Series... Read more »
Synthetic biology company Synthorx is laying plans for an initial public offering to raise money to advance its suite of enhanced cytokine drugs.
The San Diego-based company says it wants to use the proceeds to put its lead product candidate, an... Read more »
Celgene’s collaboration with Dragonfly Therapeutics is less than 18 months old, but the pharmaceutical company is already expanding the alliance.
Celgene (NASDAQ: CELG) is paying Waltham, MA-based Dragonfly $50 million upfront to add four more drug targets to the four... Read more »
Bain Capital Ventures has raised $1 billion to pour into technology companies large and small across a swath of industries, the largest single round of fundraising in the firm’s history.
The cash includes a $650 million core fund—that’ll be aimed half... Read more »
The wait is finally over.
Amazon said Tuesday it plans to significantly expand its presence in the New York City and Washington, DC, metropolitan areas beginning next year. The announcement was widely expected following news reports identifying the locales as likely... Read more »
The transformation of Johnson Controls International continues.
On Tuesday, the company said it reached a deal to sell its power solutions business, which makes a variety of vehicle batteries, in a cash transaction valued at $13.2 billion. The buyers are investment... Read more »
[Updated 11/13/18, 12:05 pm, with executive comments throughout.] The data storage wars rage on.
Boston-based primary data storage and backup provider ClearSky Data has raised $20 million in new funding to bring more customers aboard its “on-demand” hybrid cloud... Read more »
Cells have a built-in way of breaking down damaged or unneeded proteins. Kymera Therapeutics is trying to harness this process as a therapy—using it to get rid of disease-causing proteins. As the biotech prepares to test its technology in humans, it... Read more »
Most drugs target proteins in the cell, but the world of RNA has remained largely untapped by companies making chemical-based, or small-molecule drugs. That’s changing though—just in the last couple of years, there’s been a mini-boom in biotechs trying to overturn... Read more »
A little more than a month after Rethink Robotics shut down, a competitor has hired more than 20 of the Boston-based firm’s former employees.
Universal Robots, a Denmark-based maker of collaborative industrial robots, announced Tuesday it has brought on key... Read more »
Apptio is being taken private by investment firm Vista Equity Partners in a $1.94 billion acquisition.
Founded in Bellevue, WA, in 2007, Apptio (NASDAQ: APTI) helps corporate leaders track and manage IT spending. The company went public in 2016 with... Read more »
Nuance Communications is selling its document imaging division to Kofax for $400 million in cash, as Nuance’s new CEO narrows the company’s focus on its conversational artificial intelligence products and cloud-related technologies.
Nuance’s (NASDAQ: NUAN) document imaging business provides enterprise... Read more »
[Updated 11/12/18, 10:31 am, with deal terms.] Athenahealth has reached an agreement to be bought for approximately $5.7 billion in cash by private equity firms Veritas Capital and Evergreen Coast Capital, an affiliate of activist hedge fund Elliott Management.... Read more »
When Chris Meyer was enveloped by a ball of fire in a construction accident and rushed to a Madison, WI, hospital 14 months ago, his loved ones and friends feared for his life. They also worried about the future of Sector67,... Read more »
One of the biggest gambles in biotech history is about to be tested on Wall Street.
Moderna, the high-flying yet secretive developer of messenger RNA therapeutics, filed papers on Friday afternoon outlining its long-awaited IPO. In its prospectus, Moderna set an... Read more »
Acquisitions, partnerships, and an FDA approval mark this week’s roundup in Boston technology news. Read on for more:
—Boston University is adding artificial intelligence education to its electrical and computer engineering courses through a partnership with Boston A.I. company Neurala, to... Read more »
There was plenty at stake in this week’s midterm elections, and not just in terms of political wins and losses. With congress now divided—Democrats took back control of the House and Republicans extended their majority in the Senate—the implications are significant... Read more »
Xconomy Insight · Special Report
Get advice from the experts to help your biotech startup succeed
Professor, MIT
Executive VP of R&D, Biogen Idec
Founder and CEO of Kiva Systems
Founder and Managing Partner, Boston Millennia Partners
Strategic Advisor, Innovation and Strategy, Citigroup
Co-Founder & CEO, IFM Therapeutics, Inc.
Associate Provost and Professor, Dartmouth University
Lecturer, MIT
Senior Partner, Bessemer Venture Partners
General Partner, Flare Capital Partners
Visiting Scholar, MIT
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
